Randomized, double-blind, placebo-controlled pilot study of metformin as an adjunctive therapy in Parkinson’s disease
Frontiers in Pharmacology · 02.05.2025 · 16
DOI: 10.3389/fphar.2025.1497261 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 02.05.2025. Verfasst von Hayam Ali AlRasheed und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Parkinson’s disease (PD) is caused by the progressive loss of dopaminergic neurons in the substantia nigra. Neuroinflammation is considered a key factor contributing to the pathophysiology of PD. Current gold-standard therapies for PD provide only symptomatic relief without slowing disease progression, highlighting the need to develop new disease-modifying treatments. Metformin has been demonstrated to exert a neuroprotective role in several neurodegenerative disorders including PD.
Aim
This study aimed to clarify the role of metformin as adjuvant therapy in patients with PD.
Methods
Sixty patients with PD were divided into 2 groups (n = 30). Patients in group 1 received levodopa/carbidopa (250/25 mg) three times daily for 3 months plus placebo (Control group), while those in group 2 received levodopa/carbidopa (250/25 mg) three times daily and 500 mg metformin two times daily (Metformin group). Patients were assessed via Unified Parkinson’s Disease Rating Scale (UPDRS). The serum concentrations of toll like receptor 4 (TLR-4), α-synuclein, brain derived neurotropic factor (BDNF), and high mobility group box 1 (HMGB-1) were measured before and after treatment. Primary outcome The improvement in UPDRS from baseline to 3 months. Secondary outcome Change in the level of biological markers.
Results
The control group did not show significant difference in UPDRS when compared to their baseline value by Wilcoxon test ( P > 0.05), meanwhile the metformin group showed significant difference when compared to before treatment by Wilcoxon test ( P < 0.05). There were no significant differences between the two groups in UPDRS after treatment ( P > 0.05) by Man Whitney test. However, the metformin group showed a significant decrease in TLR-4, HMGB-1, and α-synuclein along with a statistically significant increase in BDNF ( P < 0.05) when compared to its baseline and control group. The control group did not show any significant changes in all markers when compared to their baseline.
Conclusion
While no significant differences in UPDRS scores were observed between the metformin and control groups, trends in biomarker changes suggest a potential impact of adjunctive metformin use on the underlying pathophysiology of PD. Further studies are needed to assess its effects on motor symptoms over a longer duration. Clinical Trial Registration identifier NCT05781711.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
- Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt.
- Pharmacology and Toxicology Department, Faculty of Pharmacy, Tanta University, Tanta, Al-Gharbia, Egypt.
- Pharmacy Practice Department, Faculty of Pharmacy, Sinai University, Arish Branch, Arish, Egypt.
- Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Al-Gharbia, Egypt.
- Department of Clinical Pharmacy, Faculty of Pharmacy, Menoufia University, Shebin El-Kom, Menoufia, Egypt.
Zitieren
APA
AlRasheed, H. A., Bahaa, M. M., Elmasry, T. A., Elberri, E. I., Kotkata, F. A., El Sabaa, R. M., Elmorsi, Y. M., Kamel, M. M., Negm, W. A., Hamouda, A. O., Aldossary, K. M., Salahuddin, M. M., Yasser, M., Eldesouqui, M., Hamouda, M. A., Eltantawy, N., Elawady, M. E., & Abdallah, M. S. (2025). Randomized, double-blind, placebo-controlled pilot study of metformin as an adjunctive therapy in Parkinson’s disease. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1497261
Vancouver
AlRasheed HA, Bahaa MM, Elmasry TA, Elberri EI, Kotkata FA, El Sabaa RM, et al. Randomized, double-blind, placebo-controlled pilot study of metformin as an adjunctive therapy in Parkinson’s disease. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1497261
BibTeX
@article{AlRasheed2025,
author = {AlRasheed, Hayam Ali and Bahaa, Mostafa M and Elmasry, Thanaa A and Elberri, Eman I and Kotkata, Fedaa A and El Sabaa, Ramy M and Elmorsi, Yasmine M and Kamel, Mostafa M and Negm, Walaa A and Hamouda, Amir O and Aldossary, Khlood Mohammad and Salahuddin, Muhammed M and Yasser, Mohamed and Eldesouqui, Mamdouh and Hamouda, Manal A and Eltantawy, Nashwa and Elawady, Mirna E and Abdallah, Mahmoud S},
title = {Randomized, double-blind, placebo-controlled pilot study of metformin as an adjunctive therapy in Parkinson’s disease},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1497261}
}
EUVIMED